



BRIDGING THE GAP

Advancing Equity and Innovation in Prostate Cancer Care in Spain

EXECUTIVE SUMMARY

Spain has built a robust and well-integrated prostate cancer care framework, supported by comprehensive screening programs, advanced diagnostic capabilities, and broad access to modern treatments. Strong clinical guidelines, well-distributed oncology services, and a high level of public awareness contribute to favorable patient outcomes. However, opportunities remain to optimize personalized medicine uptake, reduce regional variations, and further enhance survivorship support.


This policy brief examines Spain's current prostate cancer landscape and outlines strategic priorities to advance its **Level 4 – Advanced** maturity toward world-class, patient-centered care.

INTRODUCTION

Building on a Strong Foundation for Prostate Cancer Control

Prostate cancer is one of the most common cancers among Spanish men, but Spain's structured approach—anchored in population-based screening programs, advanced treatment facilities, and universal health coverage—has driven high survival rates and equitable access. Regional health systems, coordinated under national frameworks, have contributed to consistent quality standards.

Spain's challenge now lies in sustaining excellence while addressing disparities in molecular testing availability and ensuring equitable access to cutting-edge therapies across all autonomous communities.





PROSTATE CANCER IN SPAIN

Current Landscape and Strategic Gaps

Pillar	Current Status	Strength	Policy Action
Early Detection & Diagnosis	Widespread access to PSA testing and DRE through primary care, with high participation among men aged 50–69. Early-stage diagnosis is common.	Strong integration between primary care and specialist referral pathways.	Maintain screening quality while exploring AI-assisted diagnostics to improve accuracy and reduce overdiagnosis.
Biomarker & Molecular Testing	Molecular testing available in most tertiary hospitals, though access varies between regions.	Growing adoption of genomic profiling for advanced cases.	Standardize access to molecular diagnostics nationwide and integrate results into personalized treatment pathways.
Treatment Access	Broad availability of surgery, radiotherapy (including advanced modalities), hormonal therapy, and chemotherapy within the public system.	Universal health coverage ensures affordability.	Expand access to novel agents such as PARP inhibitors and PSMA-targeted radioligand therapies, ensuring timely approval and reimbursement.
Clinical Guidelines	National guidelines aligned with ESMO and NCCN best practices, regularly updated.	Strong compliance among oncology networks.	Incorporate real-world evidence into guideline updates to adapt to emerging therapies and local patient demographics.
Palliative & Survivorship Care	Well-developed palliative care services and survivorship programs integrated into oncology networks.	Strong patient support organizations.	Expand digital survivorship platforms for remote monitoring, lifestyle coaching, and psychosocial support.



CONCLUSION & Call to Action

Spain's **Level 4 – Advanced** maturity in prostate cancer care reflects a mature, integrated, and effective system with high survival rates and broad service coverage. To sustain and enhance these achievements, Spain must focus on harmonizing molecular testing access, scaling precision oncology, and optimizing survivorship support for long-term quality of life.



KEY POLICY PRIORITIES

- 1 Ensure Equity in Molecular Testing:** Mandate universal access to biomarker testing across all autonomous regions.
- 2 Accelerate Access to Innovation:** Streamline reimbursement and approval processes for next-generation therapies.
- 3 Leverage Digital Health:** Expand tele-oncology and survivorship platforms for continuous patient engagement.
- 4 Strengthen Precision Medicine Pathways:** Integrate genomic data into clinical decision-making for all eligible patients.
- 5 Maintain Screening Excellence:** Ensure high coverage, accuracy, and quality in national early detection programs.

CONCLUSION

Spain stands as a model for advanced prostate cancer care, underpinned by universal coverage, structured screening, and comprehensive treatment access. By addressing regional gaps in innovation uptake and molecular testing, the country can move toward **Level 5 – Best Practice** status, setting a benchmark for equitable, high-quality, and patient-centered prostate cancer management. With continued investment, innovation adoption, and regional equity measures, Spain can ensure that all men—regardless of geography—benefit equally from the nation's world-class prostate cancer care system.